Filter by Year:
Press Releases
-
Dec 04, 2020
Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
-
Nov 12, 2020
Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer
-
Oct 22, 2020
Foghorn Therapeutics Announces Pricing of Initial Public Offering
-
Jul 08, 2020
Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target
-
Jan 09, 2020
Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors
-
Sep 16, 2019
Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments
-
Dec 13, 2018
Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer
-
Mar 14, 2018
Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million
Displaying 51 - 58 of 58